Risk Breakdown
Financial Exposure
Governance
Double Materiality
Supply Chain
Material Risks
ESG Targets & Commitments
| Topic | Target / Metric | Status |
|---|---|---|
| Human Rights in Supply Chain | HR clauses in all contracts | Commitment |
AI Risk Summary
**Jubilant Pharmova Limited – Financial Risk Summary** Jubilant Pharmova faces critical compliance exposure under SEBI BRSR Core Expansion, with a maximum estimated remediation cost of ₹43 crore and potential enforcement action or delisting risk if disclosure obligations are not met promptly. The company's highest vulnerability stems from Extended Producer Responsibility (EPR) obligations (6.5/10 risk rating), where regulatory clarity on pharmaceutical waste management applicability remains unclear—unquantified liabilities could materially impact operating margins if new producer responsibility schemes are mandated. Current emissions data absence (zero reported Scope 1 & 2) raises audit credibility concerns; once measurement systems are implemented, carbon pricing exposure at ₹600–900/tonne could translate to significant future costs depending on actual operational intensity. Water intensity risk (5.0/10) and GHG intensity risk (5.0/10) indicate operational vulnerability, requiring immediate baseline mapping and risk mitigation to prevent regulatory penalties and maintain market valuation against sector peers.
Source: Jubilant Pharmova Limited BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.